PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Temozolomide

Drugs in development · updated 30 October 2026

Temozolomide: clinical trials and development status

Other names and codes: Temodal, Kizfizo

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 26 January 1999

As of 30 October 2026 Temozolomide is in 236 active clinical trials (recruiting or ongoing, phases I–III) for 62 diseases. The most advanced phase is III.

236Active trials
IIIMost advanced phase
62Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Temozolomide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 62 diseases.

DiseaseMost advanced phaseActive trialsReference trial
GlioblastomaIII97NCT07195591
GliomaIII36NCT00978458
Brain NeoplasmsIII24NCT00978458
AstrocytomaIII19NCT00978458
NeuroblastomaIII17NCT06172296
GliosarcomaIII12NCT05095376
MelanomaIII10NCT06346067
NeoplasmIII9NCT07195591
OligodendrogliomaIII8NCT00978458
Central nervous system neoplasmIII5NCT00978458
Neuroendocrine tumorIII5NCT07185672
GanglioneuroblastomaIII2NCT06172296
Gastro-enteropancreatic neuroendocrine tumorIII2NCT04919226
Colonic neoplasmIII1NCT06490536
Cutaneous malignant melanomaIII1NCT06743126
Neurotoxicity SyndromesIII1NCT00978458
Ewing sarcomaII10NCT05440786
RhabdomyosarcomaII10NCT06023641
MedulloblastomaII9NCT01356290
SarcomaII8NCT04200443
Lung small cell carcinomaII5NCT03672773
Diffuse Intrinsic Pontine GliomaII4NCT05096481
EpendymomaII4NCT01356290
OsteosarcomaII4NCT07444918
Islet cell adenomaII3NCT06202066
LymphomaII3NCT07015242
MetastasisII3NCT05440786
Ovarian neoplasmII3NCT06617923
Pancreatic neoplasmII3NCT07492680
Primitive neuroectodermal tumorII3NCT06861244

Everything on Temozolomide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch